• 1
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003; 53: 526.
  • 2
    Mulders P, Figlin R, deKernion JB, et al. Renal cell carcinoma: recent progress and future directions. Cancer Res. 1997; 57: 51895195.
  • 3
    Savage PD. Renal cell carcinoma. Curr Opin Oncol. 1996; 8: 247251.
  • 4
    Kirkali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. BJU Int. 2001; 68: 818824.
  • 5
    Fyfe G, Fisher RI, Rosenberg SA, Sznol A, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995; 13: 688696.
  • 6
    Guleria AS, Yang JC, Topalian SL, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol. 1994; 12: 27142722.
  • 7
    Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic disease. Cancer. 1998; 83: 797805.
  • 8
    Hawkins MJ. Interleukin-2 antitumor and effector cell responses. Semin Oncol. 1993; 20: 5259.
  • 9
    Zier KS, Gansbacher B. IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells. J Mol Med. 1996; 74: 127134.
  • 10
    Parker SE, Khatibi S, Margalith M, et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther. 1996; 3: 175185.
  • 11
    Saffran DC, Horton HM, Yankauckas AM, et al. Immunotherapy of established tumors in mice by intratumoral injection of IL-2 plasmid DNA: induction of CD8+ T cell immunity. Cancer Gene Ther. 1998; 5: 321330.
  • 12
    Stopeck AT, Hersh EM, Brailey JL, Clark PR, Norman J, Parker SE. Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes. Cancer Gene Ther. 1998; 5: 119126.
  • 13
    Galanis E, Hersh EM, Stopeck AT, et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience. J Clin Oncol. 1999; 17: 33133323.
  • 14
    Spier CM, Crogan TM, Fielder K, et al. Immunophenotypic profiles in well-differentiated lymphoproliferative disorders, with emphasis on small lymphocytic lymphoma. Hum Pathol. 1986; 17: 11261136.
  • 15
    Galanis E, Russell S. Cancer gene therapy clinical trials: lessons for the future. Br J Cancer. 2001; 85: 14321436.
  • 16
    Horn NA, Meek JA, Budahazi G, et al. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum Gene Ther. 1995; 6: 565573.
  • 17
    Rosenberg SA. Karnofsky Memorial Lecture: the immunotherapy and gene therapy of cancer. J Clin Oncol. 1992; 10: 180199.
  • 18
    Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma colony-stimulating factor gene transfer. Cancer Res. 1997; 57: 15371546.
  • 19
    Kwai K, Tani K, Asano S, Akaza H. Cancer-modified immunotherapy for renal cell carcinoma. In: HinoO, editor. Kidney cancer: recent results of basic and clinical research. Basel: Karger, 1999: 7581.
  • 20
    Nelson WG, Simons JW, Mikhak BV, et al. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol. 2000; 46: S67S72.
  • 21
    Simons JW, Mikhak B. Ex vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. Semin Oncol. 1998; 24: 661676.
  • 22
    Goey SH, Verweij J, Stoter G. Immunotherapy of metastatic renal cell cancer. Ann Oncol. 1996; 7: 887900.
  • 23
    Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon-alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med. 1998; 338: 12721278.
  • 24
    Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999; 353: 1417.
  • 25
    Young RC. Metastatic renal cell carcinoma: what causes occasional dramatic regressions? N Engl J Med. 1998; 338: 13051306.
  • 26
    Oliver RT. Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now? Br J Cancer. 1998; 77: 13181320.
  • 27
    Bubenik J, Den Otter W, Huland E. Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines. Cancer Immunol Immunother. 2000; 49: 116122.
  • 28
    Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 2000; 60: 38323837.
  • 29
    van Herpen CM, De Mulder PH. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma. Crit Rev Oncol Hematol. 2002; 41: 327334.
  • 30
    Elias L, Hunt WC. A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy. Oncology. 2001; 61: 91101.
  • 31
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 25302540.
  • 32
    Certa U, Seiler M, Padovan E, Spagnoli GC. High density oligonucleotide array analysis of interferon-α2a sensitivity and transcriptional response in melanoma cells. Br J Cancer. 2001; 85: 107114.